ID   IGR-3
AC   CVCL_Y558
AS   CVCL_GR43
SY   IGR 3; IGR3; IgR3; Institut Gustave Roussy-3
DR   BTO; BTO_0005709
DR   cancercelllines; CVCL_Y558
DR   Wikidata; Q54897364
RX   PubMed=954556;
RX   PubMed=405430;
RX   PubMed=1171141;
RX   PubMed=2337917;
RX   PubMed=4153924;
RX   PubMed=6539703;
RX   PubMed=6929009;
RX   PubMed=7520026;
RX   PubMed=8980186;
RX   PubMed=9725211;
RX   PubMed=22383533;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533).
CC   Sequence variation: Mutation; HGNC; HGNC:3432; ERBB4; Simple; p.Glu452Lys (c.1354G>A); ClinVar=VCV000091898; Zygosity=Heterozygous (PubMed=22383533).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_GR46 ! IGR-4
OI   CVCL_B5LJ ! IGR-5
SX   Male
AG   60Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 19-12-24; Version: 13
//
RX   PubMed=954556; DOI=10.1016/0014-2964(76)90033-5;
RA   Aubert C., Lagrange C., Rorsman H., Rosengren E.;
RT   "Catechols in primary and metastatic human malignant melanoma cells in
RT   monolayer culture.";
RL   Eur. J. Cancer 12:441-445(1976).
//
RX   PubMed=405430; DOI=10.1111/1523-1747.ep12496554;
RA   Foa C., Aubert C.;
RT   "Cellular localization of tyrosinase in human malignant melanoma cell
RT   lines.";
RL   J. Invest. Dermatol. 68:369-378(1977).
//
RX   PubMed=1171141; DOI=10.4049/jimmunol.115.2.539;
RA   Peter H.H., Pavie-Fischer J., Fridman W.H., Aubert C., Cesarini J.-P.,
RA   Roubin R., Kourilsky F.M.;
RT   "Cell-mediate cytotoxicity in vitro of human lymphocytes against a
RT   tissue culture melanoma cell line (IGR3).";
RL   J. Immunol. 115:539-548(1975).
//
RX   PubMed=2337917;
RA   Aquaron R., Dutoit C., Reynier M., Aubert C.;
RT   "Calmodulin content and distribution in six human melanoma cell
RT   lines.";
RL   Cell. Mol. Biol. 36:85-92(1990).
//
RX   PubMed=4153924;
RA   Janiaud P., Le Calvez J., Aubert C.;
RT   "Cytoenzymological caracterization of cells from human skin melanoma
RT   in culture.";
RL   Ann. Dermatol. Syphiligr. (Paris) 100:536-539(1973).
//
RX   PubMed=6539703; DOI=10.1016/0277-5379(84)90015-4;
RA   Weinreb A., Travo P.;
RT   "Discrimination between human melanoma cell lines by fluorescence
RT   anisotropy.";
RL   Eur. J. Cancer Clin. Oncol. 20:673-677(1984).
//
RX   PubMed=6929009; DOI=10.1093/jnci/64.5.1029;
RA   Aubert C., Rouge F., Galindo J.-R.;
RT   "Tumorigenicity of human malignant melanocytes in nude mice in
RT   relation to their differentiation in vitro.";
RL   J. Natl. Cancer Inst. 64:1029-1040(1980).
//
RX   PubMed=7520026; DOI=10.1002/ijc.2910580413;
RA   Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.;
RT   "Expression of the co-stimulatory molecule B7 on melanoma cells.";
RL   Int. J. Cancer 58:527-532(1994).
//
RX   PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#;
RA   Thomas W.D., Smith M.J., Si Z.-Y., Hersey P.;
RT   "Expression of the co-stimulatory molecule CD40 on melanoma cells.";
RL   Int. J. Cancer 68:795-801(1996).
//
RX   PubMed=9725211; DOI=10.4049/jimmunol.161.5.2195;
RA   Thomas W.D., Hersey P.;
RT   "TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in
RT   Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of
RT   target cells.";
RL   J. Immunol. 161:2195-2200(1998).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//